FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1151536748> ?p ?o ?g. }

• W1151536748 endingPage "769" @default.
• W1151536748 startingPage "754" @default.
• W1151536748 abstract "Antipsychotic medications are a central component of effective treatment for schizophrenia, but nonadherence is a significant problem for the majority of patients. Long-acting injectable (LAI) antipsychotic medications are a recommended treatment option for nonadherent patients, but evidence regarding their potential advantages has been mixed. Observational data on newer, second-generation LAI antipsychotic medications have been limited given their more recent regulatory approval and availability.To examine antipsychotic medication nonadherence, discontinuation, and rehospitalization outcomes in Medicaid patients receiving oral versus LAI antipsychotic medications in the 6 months after a schizophrenia-related hospitalization.The 2010-2013 Truven Health Analytics MarketScan Medicaid research claims database was used to identify adult patients with a recent history of nonadherence (prior 6 months) who received an oral or LAI antipsychotic medication within 30 days after an index schizophrenia-related hospitalization. Primary outcome measures were nonadherence (proportion of days covered less than 0.80), discontinuation (continuous medication gap ≥ 60 days), and schizophrenia-related rehospitalization, all in the 6 months after discharge. Descriptive analyses compared users of oral versus LAI antipsychotic medication on sociodemographic, clinical, and treatment characteristics. Logistic regressions were used to examine associations between use of oral versus LAI antipsychotics and each study outcome while controlling for observed differences in sample characteristics. All outcomes were compared at 3 levels of analysis: overall LAI class, LAI antipsychotic generation (first-generation [FGA] or second-generation [SGA] antipsychotics), and individual LAI agent (fluphenazine decanoate, haloperidol decanoate, risperidone LAI, and paliperidone palmitate).Of the final sample, 91% (n = 3,428) received oral antipsychotics, and 9.0% (n = 340) received LAI antipsychotics after discharge. Slightly over half (n =183, 53.8%) of LAI users used an SGA LAI. A smaller percentage of patients receiving LAIs were nonadherent (51.8% vs. 67.7%, P less than 0.001); had a 60-day continuous gap in medication (23.8% vs. 39.4%, P less than 0.001); and were rehospitalized for schizophrenia (19.1% vs. 25.3%, P = 0.01) compared with patients receiving oral medications. The size of these differences was magnified when comparing SGA LAI users with users of oral antipsychotics for nonadherence. After controlling for all differences in measured covariates, LAI initiators had lower odds of being nonadherent (adjusted odds ratio [AOR] = 0.35, 95% CI = 0.27-0.46, P less than 0.001) and of having continuous 60-day gaps (AOR = 0.45, 95% CI = 0.34-0.60, P less than 0.001) when compared with patients receiving oral medications. Both FGA and SGA LAI users had lower odds of nonadherence compared with patients receiving oral antipsychotics. Similarly, FGA LAI users (AOR = 0.58, 95% CI = 0.40-0.85, P = 0.005) and SGA LAI initiators (AOR = 0.34, 95% CI =0.23-0.51, P less than 0.001) had lower odds of a 60-day continuous gap compared with patients receiving oral antipsychotics. Compared with those receiving oral antipsychotics, LAI initiators also had lower odds of rehospitalization (AOR = 0.73, 95% CI = 0.54-0.99, P = 0.041); however, when examined separately, only patients receiving SGA LAIs (AOR = 0.59, 95% CI = 0.38-0.90, P = 0.015) and not FGA LAIs (AOR = 0.90, 95% CI = 0.60-1.34, P = 0.599) had a statistically significant reduction in odds of rehospitalization. Among individual LAIs, odds of rehospitalization only among initiators of paliperidone palmitate were statistically different from those among users of oral antipsychotics (AOR = 0.53, 95% CI = 0.30-0.94, P = 0.031). While odds of rehospitalization were 33% lower among patients receiving risperidone LAI compared with those receiving oral antipsychotics, the estimate did not reach statistical significance (AOR = 0.67, 95% CI = 0.37-1.22, P = 0.194). This claims-based analysis of posthospitalization adherence and rehospitalization outcomes in Medicaid patients with schizophrenia adds to the growing real-world evidence base of the benefits of LAI antipsychotic medications in routine clinical practice, particularly with regard to second-generation LAIs. As new SGA formulations become available for long-acting use, real-world studies with larger sample sizes will be needed to further delineate their potential advantages in terms of clinical outcomes and costs." @default.
• W1151536748 created "2016-06-24" @default.
• W1151536748 creator A5025358523 @default.
• W1151536748 creator A5041776912 @default.
• W1151536748 creator A5055902446 @default.
• W1151536748 creator A5065207720 @default.
• W1151536748 creator A5091820260 @default.
• W1151536748 date "2015-09-01" @default.
• W1151536748 modified "2023-10-14" @default.
• W1151536748 title "Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge" @default.
• W1151536748 cites W1670602563 @default.
• W1151536748 cites W1769482660 @default.
• W1151536748 cites W1893088267 @default.
• W1151536748 cites W1962951813 @default.
• W1151536748 cites W1967684026 @default.
• W1151536748 cites W1974150436 @default.
• W1151536748 cites W1984486655 @default.
• W1151536748 cites W1986620080 @default.
• W1151536748 cites W1989209269 @default.
• W1151536748 cites W2009566097 @default.
• W1151536748 cites W2010788532 @default.
• W1151536748 cites W2012479321 @default.
• W1151536748 cites W2020868242 @default.
• W1151536748 cites W2037135054 @default.
• W1151536748 cites W2057780602 @default.
• W1151536748 cites W2063548620 @default.
• W1151536748 cites W2065542563 @default.
• W1151536748 cites W2069024810 @default.
• W1151536748 cites W2075029547 @default.
• W1151536748 cites W2077503410 @default.
• W1151536748 cites W2087741167 @default.
• W1151536748 cites W2088866491 @default.
• W1151536748 cites W2092292003 @default.
• W1151536748 cites W2093501279 @default.
• W1151536748 cites W2096003243 @default.
• W1151536748 cites W2099226437 @default.
• W1151536748 cites W2105050750 @default.
• W1151536748 cites W2105929907 @default.
• W1151536748 cites W2108889485 @default.
• W1151536748 cites W2109070861 @default.
• W1151536748 cites W2127381871 @default.
• W1151536748 cites W2135018094 @default.
• W1151536748 cites W2136950115 @default.
• W1151536748 cites W2137175526 @default.
• W1151536748 cites W2137511087 @default.
• W1151536748 cites W2138418531 @default.
• W1151536748 cites W2139466194 @default.
• W1151536748 cites W2143285031 @default.
• W1151536748 cites W2151641071 @default.
• W1151536748 cites W2155094125 @default.
• W1151536748 cites W2159155203 @default.
• W1151536748 cites W2159582834 @default.
• W1151536748 cites W2160096204 @default.
• W1151536748 cites W2166256285 @default.
• W1151536748 cites W2187017043 @default.
• W1151536748 cites W2329828496 @default.
• W1151536748 cites W2412095319 @default.
• W1151536748 cites W2916950229 @default.
• W1151536748 doi "https://doi.org/10.18553/jmcp.2015.21.9.754" @default.
• W1151536748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26308223" @default.
• W1151536748 hasPublicationYear "2015" @default.
• W1151536748 type Work @default.
• W1151536748 sameAs 1151536748 @default.
• W1151536748 citedByCount "143" @default.
• W1151536748 countsByYear W11515367482015 @default.
• W1151536748 countsByYear W11515367482016 @default.
• W1151536748 countsByYear W11515367482017 @default.
• W1151536748 countsByYear W11515367482018 @default.
• W1151536748 countsByYear W11515367482019 @default.
• W1151536748 countsByYear W11515367482020 @default.
• W1151536748 countsByYear W11515367482021 @default.
• W1151536748 countsByYear W11515367482022 @default.
• W1151536748 countsByYear W11515367482023 @default.
• W1151536748 crossrefType "journal-article" @default.
• W1151536748 hasAuthorship W1151536748A5025358523 @default.
• W1151536748 hasAuthorship W1151536748A5041776912 @default.
• W1151536748 hasAuthorship W1151536748A5055902446 @default.
• W1151536748 hasAuthorship W1151536748A5065207720 @default.
• W1151536748 hasAuthorship W1151536748A5091820260 @default.
• W1151536748 hasBestOaLocation W11515367481 @default.
• W1151536748 hasConcept C118552586 @default.
• W1151536748 hasConcept C126322002 @default.
• W1151536748 hasConcept C2776412080 @default.
• W1151536748 hasConcept C2777126507 @default.
• W1151536748 hasConcept C2778715236 @default.
• W1151536748 hasConcept C2780057945 @default.
• W1151536748 hasConcept C2780494398 @default.
• W1151536748 hasConcept C2908997079 @default.
• W1151536748 hasConcept C71924100 @default.
• W1151536748 hasConceptScore W1151536748C118552586 @default.
• W1151536748 hasConceptScore W1151536748C126322002 @default.
• W1151536748 hasConceptScore W1151536748C2776412080 @default.
• W1151536748 hasConceptScore W1151536748C2777126507 @default.
• W1151536748 hasConceptScore W1151536748C2778715236 @default.
• W1151536748 hasConceptScore W1151536748C2780057945 @default.
• W1151536748 hasConceptScore W1151536748C2780494398 @default.
• W1151536748 hasConceptScore W1151536748C2908997079 @default.
• W1151536748 hasConceptScore W1151536748C71924100 @default.

• next